 |
12 Diseases |  |
17 Trials |
|
17 Trials |  |
2487 News |  |
| «12...89101112131415161718...2425» |
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Paralytic ileus after planned abdominal surgery in a patient on treatment with erenumab. (Pubmed Central) - Jul 9, 2021
No abstract available
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: MicroRNA Profile and Erenumab Treatment (clinicaltrials.gov) - Jul 5, 2021
P=N/A, N=40, Recruiting, Sponsor: University of L'Aquila
No abstract available Not yet recruiting --> Recruiting
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Changes in Cerebral Blood Flow after Erenumab Treatment in Good and Non-Responders-A Pilot Study of Migraine Patients. (Pubmed Central) - Jul 4, 2021
This asymmetry normalizes after the treatment with significant Vm increase in CA which may reflect CBF increase in GR only. Lower baseline Vm in right CA may predict erenumab efficacy; however, these results should be replicated in a larger cohort.
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine (clinicaltrials.gov) - Jun 30, 2021
P4, N=322, Recruiting, Sponsor: Amgen
Lower baseline Vm in right CA may predict erenumab efficacy; however, these results should be replicated in a larger cohort. Not yet recruiting --> Recruiting
- || Botox (onabotulinumtoxin A) / GSK, AbbVie, Aimovig (erenumab) / Amgen, Novartis
Review, Journal: Botulinum Toxin in the Treatment of Headache. (Pubmed Central) - Jun 24, 2021
New types of botulinum toxin selective for sensory pain neurons may well be discovered or produced by recombinant DNA techniques in the coming decade, and this may greatly enhance its therapeutic usefulness. This review summarizes the evolution of botulinum toxin use in headache management over the past several decades and its role in the preventive treatment of chronic migraine and other headache disorders.
- | Aimovig (erenumab) / Amgen, Novartis
Retrospective data, Journal, Real-world evidence: Real-World Trends in Characteristics of Patients with Migraine Newly Initiated on Erenumab in the USA: A Retrospective Analysis. (Pubmed Central) - Jun 23, 2021
Early use of erenumab post approval focused on patients with more severe disease and a high comorbidity index rating. Over time, utilization of this preventive medication occurred in a broader population of patients with migraine, with increased use by general practitioners and those outside of headache centers.
- || Review, Journal: Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today? (Pubmed Central) - Jun 22, 2021
Importantly, they are effective in subgroups of patients who have failed previous preventive therapies. Increasing use of these medications will certainly revolutionize the treatment and outlook for patients with migraine all over the world.
- | Journal: Migraine preventive treatment: monoclonal antibodies against calcitonine gene related peptide (Pubmed Central) - Jun 22, 2021
This family of drugs: erenumab, galcanezumab, fremanezumab, eptinezumab, finished Fase III, extensions trials and many of them are in the market approved since 2018.Since 2019 are available in Argentina. We will describe the rationale for the prescription of this family of new drugs for migraine.
- ||| Aimovig (erenumab) / Amgen, Novartis
I've recently been treating my hypertension and seeing a decrease in migraines so this article is timely! The Erenumab medication will be interesting to watch. (Twitter) - Jun 17, 2021
- || Retrospective data, Review, Journal: Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis. (Pubmed Central) - Jun 16, 2021
No eligible studies have investigated eptinezumab...CGRP mAbs provide highly efficacious and safe outcomes which start early after the first injection. The tolerability of these medications surpasses that of other small-molecule CGRP antagonists.
- ||| Aimovig (erenumab) / Amgen, Novartis
Slashing 186 jobs, Novartis hands off U.S. sales, marketing duties for migraine med Aimovig to Amgen https://t.co/7cQGI5ZYae (Twitter) - Jun 15, 2021
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: AMG 334 20160172 Pediatric Migraine PK Study. (clinicaltrials.gov) - Jun 10, 2021
P1, N=60, Recruiting, Sponsor: Amgen
The tolerability of these medications surpasses that of other small-molecule CGRP antagonists. Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Oct 2021 --> Apr 2022
- | Aimovig (erenumab-aooe) / Amgen, Novartis
New P1 trial, New P2 trial: Study of Intravenous Erenumab in Patients With Status Migrainosus (clinicaltrials.gov) - Jun 9, 2021
P2, N=15, Not yet recruiting, Sponsor: Mayo Clinic
- || خبر عظيم. Would you able to clarify which med was approved? Is it a preventive one (aimovig, emgality...etc) or abortive one (nurtec etc)? (Twitter) - Jun 6, 2021
- Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to OnabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine () - Jun 4, 2021 - Abstract #AHS2021AHS_389;
In this real-world study, onabotulinumtoxinA was effective at reducing MHD and the addition of a CGRP mAb was well tolerated and associated with incremental and clinically meaningful reductions in MHD for those who were able to stay on the combination. No new safety signals were identified.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Erenumab versus topiramate for the prevention of migraine: Results of a randomized active-controlled double-dummy trial () - Jun 4, 2021 - Abstract #AHS2021AHS_386;
P4
No new safety signals were identified. The results of this first head-to-head trial of a therapy targeting the CGRP pathway compared to a preventive standard-of-care therapy will provide guidance to inform clinical decision-making for the preventive treatment of migraine.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Consistent efficacy and safety of erenumab over time in patients with episodic migraine who completed a 5-year, open-label extension study () - Jun 4, 2021 - Abstract #AHS2021AHS_380;
P2
Patients receiving erenumab through 5 years of treatment demonstrated a consistent and sustained response. In this subgroup analysis of patients who completed the 5-year study, no new safety concerns were identified.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Evaluation of ischemic cardiovascular and cerebrovascular adverse events by 10-year cardiovascular risk score in patients with migraine treated with erenumab () - Jun 4, 2021 - Abstract #AHS2021AHS_379;
P2, P3
Additionally, throughout the DBTP and extension phase ICCAEs were uncommon and EAIR were similar across patients in all risk groups. This analysis helps provide more detail on the 10-year CV risk of patients in the erenumab clinical trial program.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Changes in blood pressure category with erenumab: A pooled analysis of phase 2 and phase 3 clinical trials () - Jun 4, 2021 - Abstract #AHS2021AHS_376;
P2, P3
In clinical trials, worsening of ACC/AHA guideline BP category was similar between erenumab and placebo in pts with normal BP, elevated BP, or HTN at baseline. Additional data generation is warranted to further understand the risk of worsening BP in pts with migraine and pre-existing HTN treated with erenumab.
- Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Real-world evidence for control of chronic migraine in patients meeting American Headache Society criteria who received calcitonin generelated peptide monoclonal antibody therapy added to OnabotulinumtoxinA () - Jun 4, 2021 - Abstract #AHS2021AHS_365;
This was a retrospective, longitudinal chart review of adults with CM treated at 1 clinic (October 2018November 2019) with 2 consecutive onabotulinumtoxinA cycles before 1 month of onabotulinumtoxinA plus CGRPmAb (erenumab, fremanezumab, or galcanezumab) combination treatment. Combination use of onabotulinumtoxinA and CGRPmAb demonstrated clinically meaningful improvements in headache frequency and migraine-related disability compared with onabotulinumtoxinA alone in patients with high baseline MHDs and disability treated according to AHS guidance.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Efficacy and safety of erenumab in patients with episodic migraine in East Asia: Taiwan and Korea subpopulation analysis of the EMPOwER study () - Jun 4, 2021 - Abstract #AHS2021AHS_362;
P3
The EMPOwER study showed the efficacy and safety of erenumab (70 and 140 mg) in adult patients with EM from Taiwan and Korea, consistent with the results from the global population. A consistent numerical benefit was observed with erenumab (140 mg and 70 mg) versus placebo across all efficacy endpoints.
- Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Real life experience with galcanezumab in a single tertiary headache center () - Jun 4, 2021 - Abstract #AHS2021AHS_347;
Galcanezumab reduced more than 50% of monthly days with headache in two third of our patients with refractory migraine. Switching to erenumab in non-responders, may be effective.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Effects of erenumab on non-pain symptoms in patients with chronic migraine () - Jun 4, 2021 - Abstract #AHS2021AHS_346;
P2
Switching to erenumab in non-responders, may be effective. This post-hoc analysis suggests that preventive treatment with erenumab in CM may reduce days with migraine-associated non-pain symptoms, highlighting the potential benefit of erenumab therapy in improving disease burden beyond migraine headache frequency.
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Effects of discontinuing erenumab treatment in patients with high-frequency episodic migraine and chronic migraine: Experience of a third-level headache center () - Jun 4, 2021 - Abstract #AHS2021AHS_335;
P3
Already12 weeks later, an increase in the monthly number of migraine days and in the consumption of symptomatic drugs was detectable. This change affected both patients with episodic and chronic migraine.
- Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] CGRP monoclonal antibodies along with CGRP receptor antagonists are safe and effective together and compared to standard of care () - Jun 4, 2021 - Abstract #AHS2021AHS_330;
They have also proven to have efficacy similar to onabotulinumtoxinA for chronic migraine prevention...Other than for erenumab, which works by blocking the CGRP receptor, the other three antibodies bind the CGRP molecule directly... The use of both classes of CGRP agents currently available are safe and effective and should be used together in appropriate patients.
- atogepant (AGN-241689) / AbbVie, Nurtec ODT (rimegepant ODT) / Portage
[VIRTUAL] Rimegepant versus atogepant and monoclonal antibody treatments for the prevention of migraine: A systematic literature review and network meta-analysis () - Jun 4, 2021 - Abstract #AHS2021AHS_320;
The evidence base consisted of placebo-controlled trials including the following treatments: rimegepant 75mg (oral tablet, every other day [EOD]), atogepant 10mg (oral, daily), 30mg (one or twice daily), 60mg (one or twice daily), erenumab 70mg, 140mg (subcutaneous injection [SC] monthly), galcanezumab 120mg, 240mg (SC, monthly), eptinezumab 30mg, 100mg, 300mg (intravenous infusion [IV], quarterly), and fremanezumab 225mg (SC, monthly), 675mg (SC, quarterly). Rimegepant, atogepant, and mAbs were all effective treatment options for the prevention of migraine when compared vs. placebo and generally showed similar effects when compared to one another.
- Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Crowdsourcing post-marketing safety surveillance for migraine preventives: Self-reported adverse events associated with calcitonin gene-related peptide (CGRP) therapeutics on a social media forum () - Jun 4, 2021 - Abstract #AHS2021AHS_299;
Computational linguistics applied to social media can identify potential adverse events of interest for migraine preventives. Further studies are needed to explore side effects and safety of the novel CGRP medications.
- Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Calcitonin gene-related peptide (CGRP) monoclonal antibody (MAB) wear-off phenomenon in the treatment of migraine () - Jun 4, 2021 - Abstract #AHS2021AHS_275;
Patients who trial a CGRP MAB may experience a wear-off phenomenon that is equal to approximately 25% of the anticipated time of therapeutic benefit (8 out of 30 days). Clinicians may consider documenting the use and benefit of bridge therapies during the wear-off period, and may also consider trialing a different CGRP MAB if wear-off has been identified.
- Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Patient preferences for self-injectable preventive treatments for migraine () - Jun 4, 2021 - Abstract #AHS2021AHS_269;
Preferences for autoinjectors were driven by injection duration, auto-retractability of needle removal, storage requirements and the type of autoinjector base and pinching requirements. Among self-injectable migraine preventive treatments, participants preferred a profile similar to that of galcanezumab.
- Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Adherence and persistence associated with calcitonin gene-related peptide monoclonal antibodies compared to non-calcitonin gene-related peptide monoclonal antibodies treatments for prevention of migraine () - Jun 4, 2021 - Abstract #AHS2021AHS_260;
Adults with 1 claim (first claim=index) for a CGRP mAb (galcanezumab, erenumab, fremanezumab) or non-CGRP mAb treatment (antidepressants, beta-blockers, anticonvulsants, or neurotoxin) between May 1, 2018 and June 30, 2019 with continuous enrollment in medical and pharmacy benefits for 12 months pre- and 6 months post-index were included. Patients on CGRP mAbs were more likely to be adherent and persistent compared to patients on non-CGRP mAbs.
- Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Switching associated with initiation of calcitonin gene-related peptide monoclonal antibodies versus non-calcitonin gene-related peptide monoclonal antibodies treatments for prevention of migraine () - Jun 4, 2021 - Abstract #AHS2021AHS_255;
CGRP mAb initiators were less likely to discontinue therapy over the 6-month post-index period compared to non-CGRP mAb initiators; however, out of those that discontinued, CGRP mAb initiators were more likely to switch compared to those on non-CGRP mAbs. The average time to switch was longer for those initiating CGRP mAbs compared to non-CGRP mAb initiators.
- Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Single center experience of mAbs-CGRP use for migraine prevention () - Jun 4, 2021 - Abstract #AHS2021AHS_254;
Reasons for stopping included medication failure, adverse effects, and insurance difficulties. Combined use of mAb and OnabotulinumbtoxinA seemed to be a safe and efficacious treatment of migraine.
- sumatriptan succinate / Generic mfg.
[VIRTUAL] Case report: COVID-19 nasopharyngeal swab test triggering migraines () - Jun 4, 2021 - Abstract #AHS2021AHS_202;
We suspect that the nasopharyngeal swab testing can trigger migraine through presumed sphenopalatine ganglion (SPG) irritation. In our case report, the patient was migraine-free at the time of her nasopharyngeal COVID-19 test.
- | Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Aimovig (erenumab) / Amgen, Novartis
Journal: Performance characterization of spring actuated autoinjector devices for Emgality and Aimovig. (Pubmed Central) - Jun 2, 2021
This study revealed performance differences between Emgality and Aimovig autoinjector devices, despite the fact that the delivery principle of these single-spring-actuated autoinjectors are the same. These differences may result in different risk of intramuscular injection and premature device removal, both of which need to be further verified in clinical trials.
- ||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed: DRAGON: Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients (clinicaltrials.gov) - Jun 1, 2021
P3, N=559, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
These differences may result in different risk of intramuscular injection and premature device removal, both of which need to be further verified in clinical trials. Recruiting --> Active, not recruiting
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Impact of erenumab in a Scandinavian chronic migraine population – an interim analysis of the IMPROVE phase IV trial (CBW Room) - May 30, 2021 - Abstract #EAN2021EAN_1982;
Recruiting --> Active, not recruiting The interim results thus far show an improvement of disease burden in chronic migraine patients treated with erenumab.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] The effect of Erenumab on sick leave days and healthcare visits in patients with migraine in Finland (CBW Room) - May 30, 2021 - Abstract #EAN2021EAN_1979;
The interim results thus far show an improvement of disease burden in chronic migraine patients treated with erenumab. Erenumab treatment is associated with a significant decrease in headache related sick-leave days as well as healthcare visits among occupationally active migraine patients.
- verapamil / Generic mfg., sumatriptan succinate / Generic mfg.
[VIRTUAL] Off-label use of CGRP monoclonal antibodies in patients with chronic cluster headache (Room Budapest) - May 30, 2021 - Abstract #EAN2021EAN_1457;
CGRP monoclonal antibodies may be effective in patients with chronic cluster headache. However, clinical trials are needed to prove efficacy on a large group of patients.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Efficacy and Safety of Erenumab in Indian Episodic migraine population: India subanalysis of Global EMPOwER study (Room Budapest) - May 30, 2021 - Abstract #EAN2021EAN_1454;
P3
However, clinical trials are needed to prove efficacy on a large group of patients. While the study was not powered to evaluate the efficacy of erenumab in the Indian subpopulation, the efficacy and safety profile of erenumab in Indian patients showed improvement numerically for relevant endpoints versus placebo; thus consistent with the global EMPOwER study population.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Cost offsets for erenumab responders regarding migraine healthcare resource use and productivity loss in Portugal (Room Budapest) - May 30, 2021 - Abstract #EAN2021EAN_1443;
Erenumab 140 mg brings cost-savings to society in responders (patients who stay on treatment in the mid- and long-term) due to reduced HCRU and work productivity gains. Cost offsets would become even larger if the effect of erenumab in patients’ quality of life have been accounted for in this monetary analysis.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] The SQUARE study population: Patient characteristics of erenumab-treated patients in a real-world setting in Switzerland (Room Budapest) - May 30, 2021 - Abstract #EAN2021EAN_1433;
This first interim analysis of baseline data exposes a high burden of migraine in patients seeking to initiate erenumab treatment. Subsequent data from this and other studies will evaluate the effect of erenumab in the real-world setting.
- Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] NMA of migraine day reductions with CGRP pathway-targeting mAbs in migraine patients with multiple preventive failures (Room Berlin) - May 30, 2021 - Abstract #EAN2021EAN_1393;
Fremanezumab, galcanezumab, and erenumab showed statistically significant reductions in MMD versus placebo in migraine patients with multiple prior preventive failures. No statistically significant differences were noted for fremanezumab versus erenumab or galcanezumab.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Consistent efficacy and safety of erenumab in episodic migraine patients during a 5-year, open-label extension study (Room Berlin) - May 30, 2021 - Abstract #EAN2021EAN_1391;
P2
Patients receiving erenumab over 5-years demonstrated consistent and sustained response. Safety was comparable to that observed in patients who received erenumab 70mg during the randomised phase of the trial.
- Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Real-world evidence for chronic migraine control in patients receiving treatment with CGRP mAbs and onabotulinumtoxinA (Room Berlin) - May 30, 2021 - Abstract #EAN2021EAN_1390;
This real-world study of CM patients demonstrated clinically meaningful benefits with onabotulinumtoxinA alone and additive benefits after adding CGRP mAb with no new safety signals. More real- world studies and controlled trials are needed to further quantify potential benefits of this multimodal treatment paradigm.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] A novel scoring approach to identify responders to erenumab in clinical practice (Room Budapest) - May 30, 2021 - Abstract #EAN2021EAN_821;
Here, we proposed a simple and exhaustive multidimensional score that is reliable and stable to follow- up migraine patients’ treatment response over time. The use of a simple and comprehensive score may facilitate patients’ management in clinical practice and may expand patients’ access to effective therapies.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Extreme ecchymoses in a migraine patient using concomitant treatment with erenumab and fish oil supplements (Room Budapest) - May 30, 2021 - Abstract #EAN2021EAN_805;
Erenumab has no effect on the platelets per se but may cause impaired wound healing by suppression of CGRP. Thus, small and unnoticeable bruises may aggravate instead in patients with tendency to bruises caused by for instance fish oil supplements.
- || Review, Journal: Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. (Pubmed Central) - May 28, 2021
Although all of these drugs seem highly promising for migraine treatment, their safety should be investigated in the long-term. Moreover, the exact mechanism(s) of action of these drugs need to be elucidated further, to increase both safety and efficacy and to increase the number of responders to the different treatments, so that all migraine patients can satisfactorily be treated.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Predictors of Clinical Response to Erenumab in Patients with Migraine () - May 16, 2021 - Abstract #AHS2021AHS_144;
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Risk of hypertension in erenumab-treated patients with migraine in clinical trials and in the postmarketing setting () - May 16, 2021 - Abstract #AHS2021AHS_113;
While clinical trials did not show increased risk of hypertension in patients treated with erenumab, hypertension has been reported with erenumab in the postmarketing setting. Given limitations of postmarketing AE reports, additional data are needed to fully characterize the nature of and extent to which hypertension is a risk associated with erenumab and other CGRP-pathway antagonists.
- Botox (onabotulinumtoxin A) / GSK, AbbVie
[VIRTUAL] Real-world evidence for control of patients with chronic migraine who received calcitonin gene-related peptide monoclonal antibody therapy added to OnabotulinumtoxinA treatment () - May 16, 2021 - Abstract #AHS2021AHS_111;
Combination therapy was well tolerated with no new safety signals identified. More real-world studies and controlled trials are needed to further quantify potential benefits of this multimodal treatment paradigm.